Salivary gland involvement in graft-versus-host disease: The underlying mechanism and implicated treatment

Israel Medical Association Journal

Volumn 6, Issue 3, 2004, Pages 167-172

  Nagler, Raphael M ^a,c   Nagler, Arnon ^b,d  

^a RAMBAM MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Graft versus host disease; Pilocarpine; Salivary gland; Sialochemistry; Sialometry

Indexed keywords

ALBUMIN; CALCIUM; CLOFAZIMINE; CYCLOFENIL; CYCLOSPORIN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR; ETRETINATE; HEAT SHOCK PROTEIN 70; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 8; MAGNESIUM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEDOCROMIL SODIUM; PENICILLAMINE; PHOSPHORUS; POTASSIUM; PROTEIN; RAPAMYCIN; SODIUM; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CYTOTOXICITY; DISEASE MODEL; DISEASE SEVERITY; DONOR; GASTROINTESTINAL MUCOSA; GRAFT VERSUS HOST REACTION; HUMAN; LYMPH NODE IRRADIATION; LYMPHOCYTIC INFILTRATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MOUTH HYGIENE; MOUTH INFECTION; MOUTH MUCOSA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOTOTHERAPY; PUVA; RAT; RECIPIENT; REVIEW; RODENT; SALIVARY GLAND DISEASE; SALIVATION; SJOEGREN SYNDROME; SURVIVAL; T LYMPHOCYTE; TISSUE INJURY; XEROSTOMIA;

ANIMALS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MOUTH DISEASES; MOUTH MUCOSA; PROGNOSIS; RATS; RISK ASSESSMENT; SALIVARY GLAND DISEASES; XEROSTOMIA;

EID: 1642316325     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002;100:761-7.
2. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host-disease. Blood 1997; 12:4705-9.
3. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and international bone marrow transplant registry working committee on alternative donor and stem cell sources. N Engl J Med 2000; 342: 1846-54.
4. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-93.
5. Sullivan KM, Shulman HM, Storb R. Chronic graft versus host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-76.
6. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): Chimerism testing as guidance for immune-therapeutic manipulation. Leukemia 2001;15:1967-75.
7. Shulman HM, Sale GE, Lerner KG, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978;91:545-70.
8. Janin-Mercier A, Devergie A, Van Cauwenberge D, et al. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft versus host disease in man. Am J Pathol 1984;115:296-306.
9. Nagler A, Pines M, Abadi U, et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 2000;13:641-8.
10. Han Y, Gotsman I, Pines M, et al. Induction of oral tolerance in splenocyte recipients towards pre-transplant splenocyte antigens ameliorates chronic graft versus host disease in murine model. Blood 2000;95:3613-19.
11. Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft versus host disease: Is there an alternative to the conventional treatment? [Review]. Bone Marrow Transplant 2000;25:689-96.
12. Hirozane A, Fujikura Y, Sawada T. Analysis of major histocompatibility complex [MHC] class I antigen in the rat salivary gland. Arch Oral Biol 1992;37:147-51.
13. Saitoh t, Fujiwara M, Asakura H. Ductal lesions of exocrine glands and insulitis induced by L3T4+ T cells following graft-versus-host reaction due to major histocompatibility complex class II disparity. Clin Immunol Immunopathol 1990;57:339-50.
14. Nagler R, Laufer D, Nagler A. Parotid gland dysfunction in a murine model of acute graft versus host disease. Head Neck 1998;20:58-62.
15. Nagler RM, Laufer D, Nagler A. Parotid gland dysfunction in an animal model of chronic graft-versus-host disease. Arch Otolaryngol Head Neck Surg 1996;122:1057-60.
16. Izutsu KT, Sullivan KM, Schubert MM. Disordered salivary immunoglobulin secretion and sodium transport in human graft-versus-host diseas. Transplant 1983;35:441-6.
17. Chaushu S, Chaushu G, Garfunkle AA. Immunoglobulins in recipients of bone marrow grafts. Transient secretion of donor-derived salivary IgA following major transplantation of T cell-depleted bone marrow. Bone Marrow Transplant 1994;14:925-8.
18. Fox PC, van der Van P, Sonies BC, Weijjenbach JM, Baum BJ. Xerostomia: Evaluation of a symptom with increasing significance. J Am Dent Assoc 1985;110:519-25.
19. Nagler RM, Nagler A. Sialometrical and sialochemical analysis of patients with chronic graft versus host disease - a prolonged study. Cancer Invest 2003;21(1):34-40.
20. Nakhleh RE, Miller W, Snover DC. Significance of mucosal vs. salivary gland changes in lip biopsies in the diagnosis of chronic graft-host-host disease. Arch Pathol Lab Med 1989;113:932-4.
21. Hiroki A, Nakamura S, Shinohara M, Oka M. Significance of oral examination in chronic graft-versus-host disease. J Oral Pathol Med 1994;23:209-15.
22. Nagler R, Marmary Y, Krausz Y, Chrisin R, Markitziu A, Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1996;17:219-24.
23. Norhagen G, Enstrom PE, Bjorkstrand B, Hammarstrom L, Smith CI, Ringden O. Salivary and serum immunoglobulins in recipients of transplanted allogeneic and autologous bone marrow. Bone Marrow Transplant 1994;14:229-34.
24. Nagler RM, Nagler A. The effect of pilocarpine on the constituents of saliva in patients with graft vs. host disease. Arch Oral Biol 2001;46:689-95.
25. Marti U, Burwen SJ, Jones AL. Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: An update. Hepatology 1989;9:126-38.
26. Nagler RM, Nagler A. Pilocarpine hydrochloride relieves xerostomia in chronic graft versus host disease patients: A sialometrical study. Bone Marrow Transplant 1999;23:1-5.
27. Matsuda Y, Hara J, Osugi Y, Tokimasa S, et al. Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transplant 2001;27:977-82.
28. Itoh S, Matsuzaki Y, Kimura T, et al. Suppression of hepatic lesions in a murine graft-versus-host reaction by antibodies against adhesion molecules. J Hepatol 2000;32:587-95.
29. Maruya E, Saji H, Seki S, et al. Evidence that CD31, CD49b and CD62L are immunodominant minor histocompatibility agents in HLA identical sibling bone marrow transplants. Blood 1998;92:2169-76.
30. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton L. Interferon-gamma and interleukin-6 gene polymorphous associated with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:1594-600.
31. Panoskaltsis-Mortani A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000;96:4350-6.
32. Higaki Y, Yamado O, Okamura T, Mizoguchi H, Kawashima M. Granzyme-B-containing lymphocyte involvement in epidermal injury in graft-versus-host disease. Dermatology 2001;202:94-8.
33. Serody JS, Burkett SE, Panoskaltsis-Mortari A, et al. T-lymphocyte production of macrophage inflammatory protein 1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung and spleen during graft-versus-host disease. Blood 2000;96(9):2973-80.
34. Goral J, Mathews HL, Nadler SG, Clancy J. Reduced levels of Hsp 70 result in a therapeutic effect of 15-deoxyspergualin on acute graft-versus-host disease in (DA x LE) FI rats. Immunobiology 2000;303:254-66.
35. Kichian K, Nestel FP, Kim, D, Ponka P, Lapp WS. IL-20 p40 messenger RNA expression in target organs during acute graft-versus-host disease. Possible involvement of IFN-γ. J Immunol 1996;157:2851-6.
36. Hiroki A, Nakamura S, Shinohara M, et al. A comparison of glandular involvement between chronic graft-versus-host disease and Sjögren's syndrome. Int J Maxillofac Surg 1996;25:298-307.
37. Nagler A, Nagler RM, Ackerstein S, Levy s, Marmary Y. Major salivary gland dysfunction in patients with hematological malignancies receiving interleukin-2 based immunotherapy post autologous blood stem cell transplantation [Abstract]. Bone Marrow Transplant 1997;20:575-80.
38. Brattstrom C, Tollemar J, Ringden O, Bergstrom K, Tyden G. Isoamylase levels in bone marrow transplant patients are affected are affected by total body irradiation and not by graft-versus-host disease. Transplant Int 1991;4(2): 96-8.